Table 5.
Adverse events related to anti-PD-1 treatment.
| Variable | Experimental group (n=15) |
|---|---|
| Treatment-related adverse events. | 9 (60%) |
| Grade 1–2 adverse events | 8 (53.3%) |
| Adverse events of ≥grade 3 | 1 (6.7%) |
| Serious adverse events | 1 (6.7%) |
| Serious adverse events leading to drug discontinuation | 1 (6.7%) |
| Serious adverse events leading to death | 0 |